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Abstract We analysed cyclin DI mRNA and protein expression 
in several different cell types after separating these cells 
according to their different cell cycle phases by centrifugal 
elutriation. In normal human and rat fibroblasts cyclin D1 
expression is high in early to mid G1 and decreases about 6-7 
fold before onset of replication. It has been demonstrated that 
specific transforming events, such as loss of functional retino- 
blastoma protein, overexpression of c-myc, and transfection with 
the human papillomavirns oncoproteins E6 and E7 cause 
transcriptional downregulation of cyclin D1 expression in 
logarithmically growing cells. We found that such transformed 
cells exhibit loss of the cell cycle-dependent cyclin DI fluctuation 
accompanied with reduced upregulation of cyclin D1 in G1 
phase. The data presented here provide the experimental support 
for a recently suggested model involving the function of the 
retinoblastuma protein in cyclin D1 cell cycle regulation. 
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1. Introduction 
Cyclin D1 activates the cyclin-dependent kinases 4 and 6 to 
phosphorylate the retinoblastoma protein (pRB) during G1 
phase, which leads to the activation of the transcription factor 
E2F (for recent reviews ee [1-3]). One main antagonist of this 
function of cyclin D1 is p16, the inhibitor of cyclin-dependent 
kinases 4 and 6 [4]. The recent observation that p16 is con- 
stitutively expressed throughout the ongoing cell cycle allowed 
us to postulate a model in which D-type cyclin expression is 
the main cell cycle-regulatory level of these kinase activities 
[5]. Accordingly, one would expect cyclin D1 expression to be 
high in GI and to decrease later on in the cell cycle. Never- 
theless, so far data on cell cycle regulation of cyclin D1 ex- 
pression in different cell types obtained using different syn- 
chronization procedures are conflicting. (1) In HeLa cells 
after release from a GI/S block cyclin DI mRNA begins to 
rise just after S phase, peaks around M phase and gradually 
declines during GI phase [6,7]. (2) In mammary epithelial cells 
and normal human fibroblasts, synchronized by growth factor 
deprivation and readdition, cyclin D1 mRNA and protein 
peaks in early to mid G1 [7-9]. (3) In human urinary bladder 
carcinoma cells cyclin DI peaks in early to mid G1 phase, 
shown in cells after release from a nocodazole block [10]. 
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(4) This also holds true for the murine homologue of cyclin 
D1, CYL1, analysed after CSF-1 stimulation of quiescent 
mouse macrophages. Interestingly, in these cells cyclin D1 
does not decrease any more as long as CSF-1 is present 
[11]. (5) A newly established cytofluorometric approach re- 
vealed that cyclin D1 protein is high in G1 and decreases 
before S in normal cells [12]. Furthermore, the authors ex- 
panded their analyses on B-cell tumours carrying the 
t(11 ;14) translocation, which juxtaposes cyclin D1 under the 
control of the IgH enhancer. The cyclin D1 cell cycle regula- 
tion in these tumours is identical to that in normal cells [13]. 
(6) On the other hand no cell cycle-dependent fluctuation of 
cyclin D1 expression has been observed in the human fibro- 
blast line Wl-38 released from a thymidine/aphidicolin block 
or in the myeloid cell line HL-60 [14,15]. These discrepancies 
might be related to the specific synchronisation procedures 
used or might be due to cell line-specific differences in cyclin 
D1 regulation (discussed in [15-17]). The latter must especially 
be considered since data have accumulated showing that spe- 
cific transforming events cause downregulation of cyclin D1 
expression in logarithmically growing cells. Accordingly, in 
the present report we analyse cyclin D1 cell cycle regulation 
in several cell types all separated according to the different cell 
cycle phases by centrifugal elutriation. We compare the cyclin 
D1 regulation of normal cells to that of specifically trans- 
formed cells. 
2. Materials and methods 
2.1. Cells, elutriation and FACS analysis 
All used cells and cell lines were obtained from the American Type 
Culture Collection. The cell growing conditions have been described 
in detail [18]. All cultures were routinely screened for the absence of 
mycoplasma, c-Myc overexpressing Ratl cells were kindly provided 
by M. Eilers. These cells express a protein containing the hormone- 
binding domain of the human oestrogen receptor fused to the 3' end 
of human Myc. The function of this overexpressed Myc is oestrogen- 
dependent [19]. Cells were fractionated by centrifugal elutriation as 
previously described [4,5]. Each separated fraction was monitored by 
a PAS-II flow cytometer (Partec) using 6 p.mol/l 4,6-diamidino-2- 
phenylindol-dihydrochloride to stain DNA. 
2.2. Western blot analysis 
Protein extraction and Western blot analysis were performed as 
described [20]. For imrnunodetection a anti-pRB antibody (Pharmin- 
gen, 15126E), an anti-human cyclin D1 antibody (Pharmingen, 
14726E) and an anti-mouse cyclin D1 antibody (Progen, DCS-6) 
were used. In the used cells both cyclin D1 antibodies have been 
shown not to cross-react with D2 or D3 cyclins (see also [9,10]). 
Absolute quantification of the signals was performed: each blot was 
originally exposed for different ime periods, and we chose exposures 
of comparable intensity, which still represented the linear range. The 
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signals were scanned ensitometrically, and the obtained values were 
each divided by the exposure time and normalized to p.g loaded pro- 
tein. 
2.3. Thymidine kinase assay 
Thymidine kinase activity in vitro was measured by conversion of 
radioactive thymidine to thymidine monophosphate [18]. Enzyme ac- 
tivities were normalized to total protein concentration, determined 
using the BioRad protein assay reagent with bovine serum albumin 
as a standard. 
2.4. Northern blot analysis 
RNA preparation and Northern blot procedure are described in 
[20]. The probes for hybridization were full length human and rat 
cyclin D1 cDNA and a 1300 bp cDNA fragment of the rat glycer- 
aldehyde-3-phosphate dehydrogenase (GAPDH) gene. Quantification 
of the signals was performed as described for Western analyses and 
cyclin D1 mRNA expression was normalized to GAPDH expression. 
3. Results 
3.1. Expression of cyclin D1 throughout he ongoing normal 
cell cycle 
To investigate the normal cyclin D1 cell cycle regulation, we 
chose non-transformed diploid human and rat fibroblasts. 
Since differences in the genomic organisation of the human 
and the rodent homologues of cyclin D1 have been described 
([21] and references therein), we wanted to compare cyclin D1 
cell cycle regulation in normal human and rodent cells. Loga- 
rithmically growing cells (Table 1) were separated by centri- 
fugal elutriation. About half a million cells per separated frac- 
tion were cytofluorometrically analysed for DNA distribution 
(upper panels in Fig. 2-5). As indicated by the cytofluoro- 
metric data, the separation quality of the elutriations of hu- 
man and rat fibroblasts (Figs. 2 and 3) was very comparable 
(see also Fig. 5). The first fractions contained more than 89% 
G1 cells, the best S phase fractions represented over 75% S 
phase cells, and the amount of G2 cells (also including mitotic 
cells) in the end fractions was about 76%. To further confirm 
that the separation quality was comparable and to ensure that 
the separated cells did not exhibit considerable perturbations 
of metabolic functions, we analysed thymidine kinase (TK) 
activity of each fraction. TK activity has been shown to in- 
crease at the G1/S boundary throughout the ongoing cell cycle 
[18,22]. In both cell types the cyclin D1 protein level was high 
in mid G1 and decreased about 6-7 fold before S, right at the 
time when TK activity increased (Figs. 2 and 3A). To obtain 
more information about the purity of the different elutriated 
G1 fractions we analysed the status of pRB phosphorylation 
A 
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Fig. 1. Cyclin D1 protein levels in different human (A) and rat (B) 
cells. Protein of the different cell types was denatured and reduced. 
It was run on a 12.5% SDS-PAA gel and transferred to nitrocellu- 
lose by electroblotting. Blots were stained with Ponceau-S to con- 
firm equal amounts of loaded protein. After blocking overnight at 
4°C, immunodetection was performed using anti-cyclin D1 antibody. 
Signals were developed using enhanced chemilumescence. APL, 
acute promyelocytic leukaemia cells; Y79, retinoblastoma cells; 
HeLa, cervix carcinoma cells, papillomavirus-transformed; fibros, 
normal diploid fibroblasts; U937, histiocytic lymphoma cells; Ratl, 
normal diploid fibroblasts; Ratl+c-myc, -myc overexpressing Ratl- 
MycER cells. 
in normal Ratl  cells, pRB is known to be phosphorylated in
mid G1 (reviewed in [3]). Our results, that phosphorylated 
pRB occurs for the first time in fraction 2, demonstrated 
that the first early G1 fraction does not contain significant 
contamination by later G1 cells (Fig. 3B). We further showed 
that the cell cycle-dependent fluctuation of cyclin D1 protein 
in these normal cells is paralleled by an identical mRNA os- 
cillation (Figs. 2 and 3A and Fig. 5). Taken together our data 
confirm that cyclin D1 mRNA and protein peaks in early to 
mid G1 and decreases before S throughout the ongoing cell 
cycle of normal cells and that expression of the human and 
rodent homologue of cyclin D1 oscillates identically during 
the cell cycle. 
3.2. Expression of cyclin D1 throughout the cell cycle of 
transformed cells 
Recently, data have accumulated escribing a transcrip- 
tional downregulation of cyclin D1 expression in specifically 
transformed cells. First, cells lacking functional pRB have 
been reported to express lower levels of this cyclin than their 
normal counterparts. It has been demonstrated that these cells 
do not require cyclin D1 function in G1 for proper cell cycle 
progression [23-26]. Direct proof for the role of pRB in reg- 
ulating cyclin D1 expression has been obtained by transfection 
of a reporter gene under control of the cyclin D1 promoter, 
Table 1. Cyclin D1 abundance in logarithmically growing normal and transformed cells 
Cell type and origin GI (%) S (%) G2/M ~ pRB protein Cyclin DI protein Cyclin D1 mRNA 
C%) 
Normal 
Human fibroblasts 63 22 15 + 
Ratl fibroblasts 59 28 13 + 
Transformed 
Human Y79 retinoblastoma cells 44 37 19 - 
Human HeLa cervix carcinoma cells b 46 34 20 + 
Human acute promyelocytic leukaemia cells 44 41 15 + 
Human U937 histiocytic lymphoma cells 48 37 15 ND 
Ratl fibroblasts; c-myc overexpressing 58 30 12 + 
+++ ++ 
+++ ++ 
+ + 
++ ND 
+ ND 
++ + 
~DNA distributions were determined by flow activated cell analyses. The values are means of three independent determinations. 
bHuman papillomavirus 18 (E6 and E7)-transformed cells. 
+++, detection of a very strong signal; ++, detection of a strong signal; +, detection of a weak signal; _+, detection of a very weak signal; - no 
signal detected; ND, not determined. 
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Fig. 2. Cell cycle regulation of cyclin D1 expression i normal human fibroblasts (fibros) and in human acute promyelocytic leukaemia cells 
(APL). Logarithmically growing cells were separated into fractions of different cell cycle phases by centrifugal elutriation. The fractions were 
cytofluorometrically analysed for DNA distribution (upper panel) and for cyclin D1 protein expression (compare Fig. 1). The Western blot sig- 
nals were quantified ensitometrically and related to each other by setting the highest value within one cell type at 100%. The fractions were 
also analysed for thymidine kinase activity. Enzyme activity is presented in pmol TMP formed/mg protein/h, highest value set at 100%. Abso- 
lute values of the different cells cannot be compared, since the presented blots represent different exposure times. For quantitative comparison 
see Figs. 1 and 5. In the different fractions of the normal fibroblasts cyclin D1 mRNA expression was analysed by Northern blot and related 
to glyceraldehyde-3-phosphate dehydrogenase expression (the highest value was set at 100%; lower panel, fibros). 
together with the Rb gene, into pRB-deficient cells: expression 
driven by the exogenous as well as the endogenous cyclin D1 
promoter was induced via pRB [27]. Secondly, cell transfor- 
mation by transfection with DNA tumour virus oncoproteins, 
such as SV40 large T antigen, adenovirus E1A, and papillo- 
mavirus E6/E7, also causes downregulation of cyclin D1 ex- 
pression and makes the cell cycle progression cyclin Dl-inde- 
pendent [24,28,29]. Finally, high and continuous 
overexpression of the proto-oncogene c-myc has also been 
shown to downregulate cyclin D1 expression [30,31]. Accord- 
ingly, we wanted to investigate whether this downregulation i  
transformed cells occurs to the same extent in all cell cycle 
phases and therefore does not cause alterations in cyclin D1 
cell cycle fluctuation, or whether this downregulation is ac- 
companied by changes in cyclin D1 cell cycle regulation. To 
this end, we decided to analyse the pRB-negative cell line Y79, 
human papillomavirus 18 (E6 and E7)-transformed HeLa cells 
and c-myc overexpressing Ratl fibroblasts. During logarith- 
mic growth all these cells exhibit lower levels of cyclin D1 
protein and mRNA than normal fibroblasts do (Table 1, 
Fig. 1). In our analysis we included acute promyelocytic leu- 
kaemia (APL) cells as a control for cells with very low cyclin 
D1 expression, which are transformed independently from any 
of the transformation events described above (Table 1, Fig. 1). 
Since in these APL cells cyclin D1 expression was almost 
undetectable, we had to draw larger and therefore fewer frac- 
tions after centrifugal elutriation to ensure a sufficient number 
of cells to obtain cyclin D1 Western blot signals (Fig. 2). In all 
other transformed cell types the separation quality of the cen- 
trifugal elutriations was very comparable to each other and to 
normal cells, as indicated by flowcytometric data (see also Fig. 
5) and by TK activity results (Figs. 2, 3A and Fig. 4). 
The cyclin D1 protein oscillation is lost throughout he 
ongoing cell cycle of pRB-negative Y79 cells, papilloma- 
virus-transformed HeLa cells and c-myc overexpressing Ratl 
cells (Figs. 3A, 4 and Fig. 5). Cyclin D1 mRNA does not 
fluctuate during the cell cycle of c-myc overexpressing Ratl 
cells (Fig. 3A) or Y79 cells (Fig. 4). Absolute quantitative 
comparison revealed that whereas the level of cyclin D1 ex- 
pression is comparable in the S phase fractions of normal, 
pRB-negative, papillomavirus-transformed an  c-myc overex- 
pressing fibroblasts, the upregulation of cyclin D1 in G1 is 
greatly reduced in the transformed cells (Fig. 5). These data 
strongly suggest that lower cyclin D1 expression i  these loga- 
rithmically growing transformed cells is caused by a loss of 
the transcriptional upregulation of this cyclin in G1. 
Quantitative comparison further revealed that cyclin D1 
expression in acute promyelocytic lymphocytes i lower in 
all cell cycle phases, but that these cells also express a G1- 
specific 6-7-fold upregulation of this cyclin (Figs. 2 and 5; 
APL). The observed low expression of cyclin D1 in this cell 
type might be due to its haematopoietic origin, rather than to 
its transformation status. It has earlier been shown that spe- 
cific haematopoietic cells do not express cyclin D1 ([12,23] and 
references therein). These analyses revealed that most of the 
haematopoietic cell types which express cyclin D1 were of the 
myeloid lineage whereas cyclin D1 expression was not detect- 
able in lymphoid cells. One could speculate that the low cyclin 
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Fig. 3. Cell cycle regulation of cyclin D1 expression i  normal and c-myc overexpressing Ratl fibroblasts. Ratl and Ratl-MycER were sepa- 
rated by centrifugal elutriation. (A) Cyclin D1 protein expression i  each fraction was determined by Western blot analysis and compared to 
thymidine kinase activity (compare Fig. 2). mRNA of each fraction was blotted to nylon and sequentially hybridized with cDNA probes peci- 
fic for cyclin D1 and glyceraldehyde-3-phosphate dehydrogenase (GAPDH). The Northern blot signals were densitometrically quantified and cy- 
clin D1 mRNA expression was related to GAPDH expression (the highest value was set at 100%; lower panel). Absolute values of the different 
cells cannot be compared. For quantitative comparison see Figs. 1 and 5. (B) Status of retinoblastoma protein phosphorylation in the different 
G1 fractions of elutriated Ratl cells. Protein extracts of the first four Ratl elutriation fractions presented above (A) were investigated by Wes- 
tern blot analysis using anti-retinoblastoma protein antibody, pRb, phosphorylated forms of retinoblastoma protein. 
D1 expression in our APL cells might be due to a relative 
abundance of lymphoid progenitors in this line. In this con- 
text, it might be important to note that another promyelocytic 
leukaemia cell line (HL-60) has also been shown to express 
cyclin D1 [15], whereas we did not detect cyclin D1 expression 
in the monocytic ell line U937 (Table 1, Fig. 1). 
Taken together, our data indicate that certain transforma- 
tion events, such as loss of pRB, c-myc overexpression, and 
DNA tumour virus transfection, share the capacity to abolish 
the cell cycle-dependent cyclin DI oscillation. 
4. Discussion 
We analysed cyclin D1 mRNA and protein fluctuations 
throughout he ongoing unperturbed cell cycle of different 
cell types after centrifugal elutriation. In normal cells cyclin 
D1 mRNA and protein expression is high in G1 and decreases 
6-7 fold at the G1/S boundary. This regulation is identical in 
human and rodent cells. In the present report it is demon- 
strated for the first time that cells transformed via loss of 
pRB, papillomavirus transfection or c-myc overexpression ex- 
hibit loss of this cell cycle-dependent cyclin D1 fluctuation 
accompanied with reduced upregulation of cyclin D1 in G1 
phase. Our data make it possible to map the effects of the 
studied transforming events on cyclin D1 regulation to the G1 
phase of the continuous cell cycle. The observed alterations 
are no general effect of transformation since acute promyelo- 
cytic leukaemia cells (this report) and e.g. urinary bladder 
carcinoma cells [10] exhibit the normal cyclin D1 cell cycle 
regulation. We used HeLa, Y79, and APL cells to investigate 
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Fig. 4. Cell cycle regulation of cyclin D1 expression in human pRB-negative Y79 cells and in human papillomavirus-transformed H La cells. 
Cells were separated by centrifugal elutriation. Cyclin D1 protein expression in each fraction was determined by Western blot analysis and 
compared to thymidine kinase activity (compare Fig. 2). mRNA of different fractions of elutriated Y79 cells was blotted to nylon and sequen- 
tially hybridized with cDNA probes pecific for cyclin D1 and glyceraldehyde-3-phosphate dehydrogenase (GAPDH). The Northern blot signals 
were densitometrically quantified and cyclin D1 mRNA expression was related to GAPDH expression (the highest value was set at 100%; lower 
panel, Y79). 
the consequences of the according transformation events for 
cyclin D1 cell cycle expression, since those cell lines were al- 
ready analysed for cyclin D1 regulation during random 
growth [8,15,23]. The Ratl-MycER cells enabled us to selec- 
tively connect he observed alterations of cyclin D1 cell cycle 
regulation to the function of the proto-oncogene c-myc 
[19,30,31]. The detailed description of the regulation of p16 
and pRB expression, as well as of E2F-dependent transcrip- 
tion in the used cell lines [4,5,8,15,22,23,31,33] further facili- 
tated the conclusion of a causal connection between the trans- 
formation events the cell lines were derived from, and cyclin 
D1 deregulation. 
Our data very strongly support a recently suggested model 
for cyclin D1 cell cycle regulation [24,27]: transcription from 
the cyclin D1 promoter is driven, directly or indirectly, by the 
underphosphorylated form of pRB, present in early and mid 
G1. Inactivation of pRB via phosphorylation i late G1 
would shut off cyclin D1 transcription. Our observed cell cy- 
cle-dependent fluctuation of cyclin DI expression in normal 
cells is in perfect agreement with this hypothesis. It has further 
been concluded that tight complex formation with a viral 
oncoprotein would occupy the available pRB pockets in G1, 
thereby preventing pRB's normal activating role for cyclin D1 
expression. In line with this model, one would expect that 
cyclin DI expression can also not be induced in the G1 phase 
of pRB-negative cells. Our quantitative comparison revealed 
that whereas the levels of cyclin D1 protein and mRNA ex- 
pression in S phase of normal fibroblasts, pRB-negative, and 
DNA tumour-virus transformed cells are comparable, the ob- 
served G1 induction of cyclin D1 expression in normal fibro- 
blasts is greatly diminished in these transformed cells (Fig. 5). 
This observation can be perfectly explained by the postulated 
model. In this context it is important to note that very recent 
data demonstrated that pRB-deficient cells do not express 
lower levels of cyclin D1 than their normal counterparts, in- 
dicating that loss of pRB is necessary but not sufficient o 
downregulate cyclin D1 expression [26,32]. 
Our data that c-myc causes a decrease of cyclin D1 in loga- 
rithmically growing cells are in agreement with results of other 
groups: more detailed molecular analyses have revealed that 
repression of cyclin D1 by c-mye does not require association 
of Myc and Max in vivo, occurs at the level of transcription 
and is mediated by core elements of the cyclin D1 promoter. 
Interestingly, the authors showed that a small domain in the 
amino terminus of c-myc with structural similarity to the ami- 
no terminus of E1A is critical for repression of cyclin D1 
[30,31]. The exact molecular mechanism of how overexpres- 
sion of c-myc causes downregulation of cyclin D1 is still un- 
clear. It has recently been demonstrated that, unlike onco- 
genes of DNA tumour viruses, constitutive xpression of 
Myc does not relieve the requirement for cyclin D1 function 
[33]. These data allow the conclusion that Myc's role in D1 
regulation is different from that played by DNA tumour virus 
oncogenes. Nevertheless, ince very recently published data 
demonstrate hat pRB phosphorylation is a downstream tar- 
get of c-myc [33], the possibility that pRB is involved in the 
cascade of cyclin D1 downregulation via c-myc has still to be 
kept in mind. 
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